EBioMedicine · 2022 · 85 citations · 19 references
MedicineCardiologyMolecular GeneticsCardiovascular GeneticsInflammationMedical GeneticsAcute Coronary SyndromesCardiovascular DiseaseGenetic RiskIschemic Heart DiseaseMyocardial Infarction ComplicationsCardiovascular Disease IncidenceCardiovascular Disease MortalityCardiovascular Disease PrevalenceDeep Sequencing AnalysisMyocardial Infarction GeneticsVariant Allele Frequency AnalysisVariant Allele Frequency EstimationVariant Allele Frequency Interpretation
BACKGROUND: Clonal haematopoiesis driven by mutations in DNMT3A or TET2 has recently been identified as a new risk factor for cardiovascular disease. Experimental studies suggest that these mutations may enhance inflammation which accelerates the disease progression. We aim to investigate the prevalence of mutations in DNMT3A and TET2 and their association with prognosis of patients with ST-segment elevation myocardial infarction (STEMI). METHODS: Targeted deep sequencing for DNMT3A and TET2 and inflammatory cytokines (IL-1β, IL-6, TNF-α, INF-γ) were analyzed in 485 patients with STEMI. Major adverse cardiac events (MACE) was a composite of death, myocardial infarction, stroke, or hospitalization due to heart failure. FINDINGS: Patients carrying DNMT3A- or TET2-CH-driver mutations with a variant allele frequency (VAF) ≥2% were found in 12.4% (60 of 485) of STEMI patients and experienced an increased incidence of the death (30.9% vs 15.5%, P = 0.001) and MACE (44.5% vs 21.8%, P < 0.001) compared to those who did not, during a median follow up of 3.0 (interquartile range: 2.4-3.4) years. After adjusting for confounders, mutation remained an independent predictor of death (HR = 1.967, 95% CI 1.103-3.507, P = 0.022) and MACE (HR = 1.833, 95% CI 1.154-2.912, P = 0.010). Concentrations of plasma IL-1β (P = 0.010) and IL-6 (P = 0.011) were significantly elevated in DNMT3A/TET2 VAF≥2% group. INTERPRETATION: DNMT3A- or TET2-CH-driver mutations with a VAF≥2% were observed in over 10% STEMI patients, and were significantly associated with poorer prognosis, which might be explained by higher levels of inflammatory cytokines in mutations carriers. FUNDING: National Natural Science Foundation of China; National Key R&D Program of China.
19
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick et al. · New England Journal of Medicine · 2014 · 4.7K citations · Full text
Life Sciences, Genetics, Hematology +17
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean‐Claude Tardif, Simon Kouz, David D. Waters et al. · New England Journal of Medicine · 2019 · 3K citations · Full text
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Siddhartha Jaiswal, Pradeep Natarajan, Alexander J. Silver et al. · New England Journal of Medicine · 2017 · 2.6K citations · Full text
Medicine, Cardiology, Hematology +16
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma, Rafael Bejar, Siddhartha Jaiswal et al. · Blood · 2015 · 1.9K citations · Full text
Medicine, Hematology, Pathology +16